FOLH1 and neoplasm: 18F-MD-PSMA is stable in vitro, easy to produce, has delayed renal excretion associated with more favorable distribution in the abdomen and pelvis, has lower background, has a higher tumor-to-background ratio for positive lesions, and has been proven to be safe for patients.